Human Immunoglobulin E specific for Mangifera indica pollen allergens (Anti-Man i IgE)

Human Immunoglobulin E (IgE) antibodies specific for Mangifera indica (mango) pollen epitopes are the primary mediators of Type I hypersensitivity reactions in sensitized individuals (Source: PMID: 25611437). These antibodies recognize specific allergenic proteins within the pollen, most notably Man i 1 (profilin), Man i 2 (thaumatin-like protein), and Man i 3 (polocalcin) (Source: WHO/IUIS Allergen Nomenclature). Upon inhalation of mango pollen, these allergens cross-link specific IgE molecules bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils. This cross-linking triggers the immediate release of inflammatory mediators like histamine and leukotrienes (Source: PMID: 30103934). The resulting physiological response leads to clinical manifestations such as allergic rhinitis, conjunctivitis, and exacerbation of bronchial asthma (Source: PMID: 15584111). These specific IgE antibodies serve as critical biomarkers for diagnosis via serum assays or skin prick tests. They are also the functional targets for therapeutic interventions aimed at reducing allergic inflammation. Monoclonal antibodies such as Omalizumab work by binding to the Fc region of free IgE, preventing its interaction with receptors on effector cells (Source: FDA Label for Xolair). This sequestration of IgE effectively reduces the allergic cascade regardless of the specific allergen involved. Understanding these specific antibodies is essential for developing targeted allergen-specific immunotherapy (SIT) for mango pollen allergy.

Other names

Mango pollen-specific IgEHuman IgE anti-Man iImmunoglobulin E specific for mango pollenAnti-mango pollen IgE

Anti-IgE monoclonal antibodies bind to the Cε3 domain of free circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, which inhibits the release of allergic mediators.